Back to news

BillionToOne (BLLN) Faces Investor Scrutiny Related to Short Report Allegations Driving Shares Lower – HBSS

Globe Newswire•19/11/2026•16:08 ET
0

Key Highlights

  • ➤False Claims Act fines could exceed $1.2 billion, Fuzzy Panda alleges
  • ➤BillionToOne shares fell over 6% after the short report
  • ➤Prenatal testing generated about 85% of BillionToOne’s $122 million revenue
  • ➤Hagens Berman opened an investigation into BillionToOne’s billing disclosures

Expert Statements

Reed Kathrein, Hagens Berman partner leading the investigation

“We’re focused on the report’s allegations and, if true, whether BillionToOne may have violated the securities laws”

SAN FRANCISCO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- On November 18, 2026, short seller Fuzzy Panda Research published a critical report on BillionToOne (NASDAQ: BLLN) challenging the company’s disclosures and claiming it could face False Claims Act fines in excess of $1.2 billion. In response, investors saw the price of their shares fall over 6%.

The developments have prompted national shareholders rights firm Hagens Berman to open an investigation into whether BillionToOne has been sufficiently transparent about its billing patterns.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in